NLS Pharmaceutics Analyst Ratings
NLS Pharmaceutics Analyst Ratings
While ratings are subjective and will change, the latest NLS Pharmaceutics (NLSP) rating was a downgraded with a price target of $0.00 to $0.00. The current price NLS Pharmaceutics (NLSP) is trading at is $0.82, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/14/2023 | — | Maxim Group | Downgrades | Buy → Hold | |
| 12/08/2022 | 387.75% | Maxim Group | → $4 | Upgrades | Hold → Buy |
| 11/08/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 09/06/2022 | 631.62% | Laidlaw & Co. | → $6 | Initiates Coverage On | → Buy |
| 03/12/2021 | 1363.24% | Brookline Capital | → $12 | Initiates Coverage On | → Buy |
| 03/03/2021 | 875.49% | Maxim Group | → $8 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行空間 | 分析師公司 | 價格目標變化 | 評級變化 | 之前/現今評級 |
|---|---|---|---|---|---|
| 09/14/2023 | — | Maxim Group | 降級 | 買入 → 持有 | |
| 12/08/2022 | 387.75% | Maxim Group | → $4 | 升級 | 持有 → 買入 |
| 11/08/2022 | — | Maxim Group | 降級 | 買入 → 持有 | |
| 09/06/2022 | 631.62% | 利德洛證券 | → $6 | 開始覆蓋 | → 買入 |
| 03/12/2021 | 1363.24% | 布魯克線資本 | → $12 | 開始覆蓋 | → 買入 |
| 03/03/2021 | 875.49% | Maxim Group | → $8 | 開始覆蓋 | → 買入 |
What is the target price for NLS Pharmaceutics (NLSP)?
NLS Pharmaceutics (NLSP)的目標價是多少？
The latest price target for NLS Pharmaceutics (NASDAQ: NLSP) was reported by Maxim Group on September 14, 2023. The analyst firm set a price target for $0.00 expecting NLSP to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.
NLS Pharmaceutics (NASDAQ: NLSP)的最新目標價是由Maxim Group於2023年9月14日發佈的。該分析公司設定了$0.00的目標價，預計NLSP在12個月內可能下跌-100.00%。在過去的一年中有3家分析公司報告了評級。
What is the most recent analyst rating for NLS Pharmaceutics (NLSP)?
NLS Pharmaceutics (NLSP)的最新分析師評級是什麼？
The latest analyst rating for NLS Pharmaceutics (NASDAQ: NLSP) was provided by Maxim Group, and NLS Pharmaceutics downgraded their hold rating.
NLS Pharmaceutics (NASDAQ: NLSP)的最新分析師評級是由Maxim Group提供的，NLS Pharmaceutics下調了持有評級。
When is the next analyst rating going to be posted or updated for NLS Pharmaceutics (NLSP)?
NLS Pharmaceutics (NLSP)的下一個分析師評級什麼時候發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NLS Pharmaceutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NLS Pharmaceutics was filed on September 14, 2023 so you should expect the next rating to be made available sometime around September 14, 2024.
分析師經過廣泛的研究後才得出股票評級，其中包括查閱公開的基本報表，與NLS Pharmaceutics的管理人員和客戶交談，以及聽取業績會議的通話。大多數分析師每三個月進行一次評級，因此您應該每年得到每家公司每個機構4個評級。NLS Pharmaceutics的最後評級是在2023年9月14日提交的，因此您應該期望下一個評級在2024年9月14日左右發佈。
Is the Analyst Rating NLS Pharmaceutics (NLSP) correct?
NLS Pharmaceutics (NLSP)的分析師評級正確嗎？
While ratings are subjective and will change, the latest NLS Pharmaceutics (NLSP) rating was a downgraded with a price target of $0.00 to $0.00. The current price NLS Pharmaceutics (NLSP) is trading at is $0.82, which is out of the analyst's predicted range.
雖然評級是主觀的且會變化，但最新的NLS Pharmaceutics (NLSP)評級是下調的，目標價爲$0.00至$0.00。目前NLS Pharmaceutics (NLSP)的交易價格爲$0.82，超出了分析師預測的區間。